Key result
Amlodipine combination therapy reduces BP and CV events in high-risk patients.
This review highlights the established cardiovascular benefits of amlodipine combined with diuretics or ACE inhibitors, and notes the need for outcome data for combinations with newer RAAS blockers.
Supports amlodipine combinations in high-risk hypertension; leaves open dedicated outcome trials with newer RAAS blockers.
Amlodipine is a long-acting, dihydropyridine calcium antagonist now widely used for lowering of elevated blood pressure. In recent years it has been shown to be effective in reducing both blood pressure and risk of cardiovascular (CV) events when used in combination with other antihypertensive agents of different classes. Strong evidence of cardiovascular benefit has been attained for combination of amlodipine with diuretics or angiotensin converting enzyme (ACE) inhibitors in a number of high-risk CV groups, including those with established coronary artery disease, diabetes, and at risk of renal disease. Combination therapies of amlodipine with other agents eliciting renin-angiotensin-aldosterone system blockade (angiotensin II receptor blockers or renin inhibitors) have been shown to be effective blood pressure-lowering strategies, but await the results of ongoing trials for direct evidence of benefit for renal disease progression and CV morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Owen et al. (2012) conducted a review in Elevated blood pressure. Amlodipine was evaluated. Amlodipine combined with other antihypertensive agents effectively reduces blood pressure and cardiovascular events in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: